brazzo / iStockphoto.com

13 December 2018Biotechnology

Conference preview: 11th Pharma & Biotech Patent Litigation

We are entering a new era for European patent litigation which will have resounding effects on the life sciences industry.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

Trump’s return sparks calls for pro-patent agenda

Amgen faces pushback over bid to narrow patent scope

LSPN Europe: Navigating the EPO and lessons from the UPC frontline